Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3038488 Target Snapshot

Kir3.1/Kir3.4 · PROTEIN COMPLEX · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
395Compounds
30Assays
0Approved Drugs
382.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Kir3.1/Kir3.4 shows approved-linked disease relevance led by atrial fibrillation. 1 more disease program remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P48549. Start with atrial fibrillation, then reuse UniProt P48549 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with atrial fibrillation, then reuse UniProt P48549 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
atrial fibrillation

Kir3.1/Kir3.4 shows approved-linked disease relevance led by atrial fibrillation. 1 more disease program remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with atrial fibrillation because it currently carries approved-linked support. Linked drugs include VERNAKALANT HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Protein anchor
G protein-activated inward rectifier potassium channel 1

G protein-activated inward rectifier potassium channel 1

Review this target as Kir3.1/Kir3.4, mapped to UniProt P48549. ChEMBL maps the protein component as G protein-activated inward rectifier potassium channel 1. Sequence length is 501 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt P48549 Protein 501 aa
Open protein block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Kir3.1/Kir3.4 as ChEMBL target CHEMBL3038488, mapped to UniProt P48549. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Kir3.1/Kir3.4
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3038488
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P48549
G protein-activated inward rectifier potassium channel 1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Kir3.1/Kir3.4 is the right protein anchor across sources, using UniProt P48549 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why atrial fibrillation is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameKir3.1/Kir3.4
Target TypePROTEIN COMPLEX
OrganismHomo sapiens
UniProtP48549
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelG protein-activated inward rectifier potassium channel 1
UniProt AccessionP48549
Component TypeProtein
Sequence Length501 aa

G protein-activated inward rectifier potassium channel 1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Kir3.1/Kir3.4, mapped to UniProt P48549. ChEMBL maps the protein component as G protein-activated inward rectifier potassium channel 1. Sequence length is 501 aa.

Mapped IDP48549
Review nameKir3.1/Kir3.4
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Kir3.1/Kir3.4 shows approved-linked disease relevance led by atrial fibrillation. 1 more disease program remain visible in the same review block.

Approved-linked Approved
atrial fibrillation
1 linked drug · 1 direct · 1 efficacy
Linked drugVERNAKALANT HYDROCHLORIDE
Late clinical Phase III
atrial flutter
1 linked drug · 1 direct · 1 efficacy
Linked drugVERNAKALANT HYDROCHLORIDE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with atrial fibrillation because it currently carries approved-linked support. Linked drugs include VERNAKALANT HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseatrial fibrillation
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC50206.0
KI1.0
EC50175.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5281961 8.7 IC50 2.0 Preclinical
CHEMBL5991011 8.22 IC50 6.0 Preclinical
CHEMBL6049828 8.1 IC50 8.0 Preclinical
CHEMBL4559408 8.09 Ki 8.2 Preclinical
CHEMBL5287217 8.05 IC50 9.0 Preclinical
CHEMBL5856252 8.05 IC50 9.0 Preclinical
CHEMBL5280047 7.96 IC50 11.0 Preclinical
CHEMBL5933498 7.96 IC50 11.0 Preclinical
CHEMBL5904969 7.89 IC50 13.0 Preclinical
CHEMBL5964704 7.89 IC50 13.0 Preclinical
Distribution

pChEMBL Value Distribution

41
5.0
73
5.5
80
6.0
56
6.5
32
7.0
22
7.5
6
8.0
1
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

30
Total Assays
315
Tested Compounds
1
Assay Types
Binding — 30 assays, 315 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 16 125 5.9
protein complex format 11 98 6.0
assay format 3 92 7.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine